Mitomycin Pyelocalyceal
(Redirected from Jelmyto)
What is Mitomycin Pyelocalyceal?[edit | edit source]
- Mitomycin Pyelocalyceal (Jelmyto) is an alkylating drug used for the treatment of adult patients with low-grade UpperTract Urothelial Cancer (LG-UTUC).
What are the uses of this medicine?[edit | edit source]
- Mitomycin Pyelocalyceal (Jelmyto) is used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).
How does this medicine work?[edit | edit source]
- Mitomycin inhibits the synthesis of deoxyribonucleic acid (DNA).
- The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking.
- At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients:
- who have a hole or tear (perforation) of your bladder or upper urinary tract.
What drug interactions can this medicine cause?[edit | edit source]
- Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
Be sure to mention any of the following:
- diuretics ('water pills')
Is this medicine FDA approved?[edit | edit source]
- In April 2020, mitomycin gel, sold under the brand name Jelmyto, was approved in the United States for the treatment of low-grade upper tract urothelial cancer (UTUC).
- Urothelial cancer is a cancer of the lining of the urinary system.
How should this medicine be used?[edit | edit source]
- Administer 1.3 g of sodium bicarbonate orally the evening prior to, the morning of, and 30 minutes prior to instillation procedure (total of 3.9 g).
Recommended dosage:
- The dose of JELMYTO to be instilled is 4 mg per mL via ureteral catheter or nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).
- Instill JELMYTO once weekly for six weeks.
- For patients with a complete response 3 months after JELMYTO initiation, JELMYTO instillations may be administered once a month for a maximum of 11 additional instillations.
Administration:
- JELMYTO is for pyelocalyceal use only and not for intravenous use, topical use, or oral administration.
- JELMYTO will be given to you by your healthcare provider.
- You will receive JELMYTO 1 time a week for 6 weeks.
- It is important that you receive all 6 doses of JELMYTO according to your healthcare provider's instructions.
- Your healthcare provider may recommend up to an additional 11 monthly doses.
- JELMYTO is given to your kidney through a tube called a catheter.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As pyelocalyceal solution
This medicine is available in fallowing brand namesː
- JELMYTO
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
- urinary tract infection
- blood in your urine
- side pain
- nausea
- trouble with urination
- kidney problems
- vomiting
- tiredness
JELMYTO may cause serious side effects, including:
- ureteric obstruction
- Bone marrow problems
What special precautions should I follow?[edit | edit source]
- Ureteric obstruction, including ureteral stenosis and hydronephrosis, occurred in patients receiving JELMYTO. Monitor patients for signs and symptoms of ureteric obstruction. Transient or long-term ureteral stents or alternative procedures may be required. Withhold or permanently discontinue JELMYTO based on the severity of the ureteric obstruction.
- The use of JELMYTO can result in bone marrow suppression, particularly thrombocytopenia and neutropenia. Thrombocytopenia and neutropenia may occur. Monitor blood counts. Withhold or permanently discontinue JELMYTO based on the severity.
- Based on findings in animals and mechanism of action, JELMYTO can cause fetal harm when administered to a pregnant woman. Advise of potential risk to a fetus and to use effective contraception.
- Advise women not to breastfeed during treatment with JELMYTO and for 1 week following the last dose
- Advise patients that JELMYTO contains mitomycin which is a violet to blue color and may discolor urine following the instillation procedure.
- Advise patients to avoid contact with urine for at least six hours post-instillation.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO.
- Advise pregnant women of the potential risk to a fetus.
Can this medicine be used in children?[edit | edit source]
- Safety and efficacy in pediatric patients have not been established.
What are the active and inactive ingredients in this medicine?[edit | edit source]
- Active ingredient: mitomycin
- Inactive ingredients: hydroxypropyl methylcellulose, mannitol, poloxamer, polyethylene glycol, and water for injection
Who manufactures and distributes this medicine?[edit | edit source]
Distributed by:
- UroGen Pharma, Inc.
- Princeton, NJ
- JELMYTO® and UroGen® are registered trademarks of UroGen Pharma, Ltd.
What should I know about storage and disposal of this medication?[edit | edit source]
- Store the JELMYTO carton at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
- Avoid excessive heat over 40°C (104°F).
- JELMYTO is a cytotoxic drug.
- Follow applicable special handling and disposal procedures
Mitomycin Pyelocalyceal Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju